Exagen Diagnostics files IPO plans; Genetic tests identifying cancer risks outpace understanding of results;

> Exagen Diagnostics has filed plans to raise up to $69 million in an initial public offering. Story

> Genetic tests that identify mutations that may point to cancer risk are outpacing the understanding of what they mean. Story (sub. req.)

> The Washington state life sciences industry has surpassed $1 billion in transactions, including going public, acquisitions and licensing deals. Story

> Researchers have developed a biosensor made from graphene that can identify biomarkers pointing to an increased risk of developing cancer. Item

> The FDA has formally announced an emergency-use authorization for an in vitro diagnostic device to detect the Ebola virus. Notice

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.